Announcements Trials
Browse Landscape

Phase

Phase NA 56Phase 2 20Phase 4 15Phase 1 10Phase 3 7Phase EARLY_PHASE1 5Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 7Thyroid Carcinoma, Anaplastic 3Thyroid Cancer, Papillary 3Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Thyroid Neoplasms 2Somatostatinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Laryngeal Neoplasms 2Hematologic Neoplasms 2Glioma 2Gastroenteropancreatic Neuroendocrine Tumors 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2Vipoma 1Thyroid cancer, Hurthle cell 1Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Muscle Weakness 1Motor Activity 1Melanoma 1

Interventions

Temozolomide 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Pituitary Neoplasms × Endocrine × Clear all
NCT04244708 2020-01-28

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Peking Union Medical College Hospital

Phase 2/3 Unknown
150 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡